Bio-Rad Stock Drops 16.8 Percent Amid Broad Decline in Index | GenomeWeb
Shares in Bio-Rad dropped 16.8 percent for the five-day trading period ended Tuesday. The firm’s shares took a hit due to an underwhelming financial forecast during its fourth-quarter conference call last week (see related article, this issue), and a drop in stocks across the board. Luminex was the other member of the BCW Index to decline by double-digit figures, falling 11.1 percent for the tracking period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.